Shaobo Yao1, Haiqun Xing1, Wenjia Zhu1, Zhanhong Wu2, Yingqiang Zhang1, Yanru Ma1, Yimin Liu1, Li Huo1, Zhaohui Zhu1, Zibo Li2, Fang Li3. 1. Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, 100730, China. 2. Department of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, NC 27599, USA. 3. Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, 100730, China. Electronic address: lifang@pumch.cn.
Abstract
PURPOSE: The noninvasive imaging of bacterial infections is critical in order to reduce mortality and morbidity caused by these diseases. The recently reported (18)F-FDS ((18)F-2-fluorodeoxy sorbitol) as a PET (positron emission tomography) tracer can be used to image Enterobacteriaceae-specific infections and provides a potential alternative to this problem compared with other probes for imaging infections. In this study, automatic synthesis, validation of (18)F-FDS and a first-in-human study were performed and discussed. METHODS: A multifunctional synthesis module was employed for the radiosynthesis of (18)F-FDG ((18)F-2-fluorodeoxy glucose) and (18)F-FDS starting from (18)F ion using two-pot three-step fully automated reactions. The behavior of (18)F-FDS as an in vivo imaging probe for infections was evaluated in an Escherichia coli mouse infection model. The first detailed pharmacokinetic and biodistribution parameters were obtained from healthy human volunteers. RESULTS: The uptake of (18)F-FDS in an E. coli mouse-myositis infection model was easily differentiated from other organs and normal muscle. Intensive lesion uptake declined after antibiotic treatment. In the pilot human study, no adverse effects due to (18)F-FDS were observed up to 24 h post-injection. The radiotracer was rapidly cleared from the circulation and excreted mainly through the urinary system. CONCLUSION: We conclude that (18)F-FDS PET holds great potential for appropriate and effective for the imaging of bacterial infections in vivo. These preliminary results indicate that further clinical studies are warranted.
PURPOSE: The noninvasive imaging of bacterial infections is critical in order to reduce mortality and morbidity caused by these diseases. The recently reported (18)F-FDS ((18)F-2-fluorodeoxy sorbitol) as a PET (positron emission tomography) tracer can be used to image Enterobacteriaceae-specific infections and provides a potential alternative to this problem compared with other probes for imaging infections. In this study, automatic synthesis, validation of (18)F-FDS and a first-in-human study were performed and discussed. METHODS: A multifunctional synthesis module was employed for the radiosynthesis of (18)F-FDG ((18)F-2-fluorodeoxy glucose) and (18)F-FDS starting from (18)F ion using two-pot three-step fully automated reactions. The behavior of (18)F-FDS as an in vivo imaging probe for infections was evaluated in an Escherichia colimouseinfection model. The first detailed pharmacokinetic and biodistribution parameters were obtained from healthy human volunteers. RESULTS: The uptake of (18)F-FDS in an E. colimouse-myositis infection model was easily differentiated from other organs and normal muscle. Intensive lesion uptake declined after antibiotic treatment. In the pilot human study, no adverse effects due to (18)F-FDS were observed up to 24 h post-injection. The radiotracer was rapidly cleared from the circulation and excreted mainly through the urinary system. CONCLUSION: We conclude that (18)F-FDS PET holds great potential for appropriate and effective for the imaging of bacterial infections in vivo. These preliminary results indicate that further clinical studies are warranted.
Authors: Matthew F L Parker; Robert R Flavell; Justin M Luu; Oren S Rosenberg; Michael A Ohliger; David M Wilson Journal: ACS Infect Dis Date: 2020-06-09 Impact factor: 5.084
Authors: Mausam Kalita; Matthew F L Parker; Justin M Luu; Megan N Stewart; Joseph E Blecha; Henry F VanBrocklin; Michael J Evans; Robert R Flavell; Oren S Rosenberg; Michael A Ohliger; David M Wilson Journal: J Labelled Comp Radiopharm Date: 2020-03-28 Impact factor: 1.921